New strategy aims to shield myeloma patients from dangerous virus during treatment
NCT ID NCT06920251
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether the antiviral drug letermovir can prevent a common and serious viral infection called CMV in people with relapsed/refractory multiple myeloma who are receiving the immunotherapy elranatamab. The trial will enroll 40 adults who are CMV-positive. Researchers will monitor how many patients develop a significant CMV infection during treatment. If letermovir works, it could become a standard preventive measure for these patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Letermovir (an antiviral drug) and elranatamab (a cancer immunotherapy)
What this could lead to
If successful, this could provide a way to prevent a serious viral infection (CMV) in multiple myeloma patients undergoing treatment, reducing hospitalizations and complications.
What could go wrong
This is a small, early-phase study with only 40 participants, so results may not apply to all patients. The drug may not effectively prevent CMV or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••